Biological preparation that improves immunity to a particular disease

Vaccines which use killed or inactivated germs are called dead or inactivated vaccines. Other types are subunit vaccines, which only use parts of germs.

The global vaccines market is expected to reach $57.50 billion by 2025 from $33.70 billion in 2018, growing at a CAGR of 7.9%

The growth of this market is mainly attributed to high prevalence of diseases, increasing government initiatives towards immunization, rising adoption of vaccines, technological advancements in vaccine industry, and strong pipeline for vaccines. In addition, increasing epidemic potentials and growing focus on therapeutic vaccines are expected to offer significant growth opportunities for players operating in the vaccines market.

In 2017, pneumococcal disease accounted for the largest share of the vaccines market. The large share of this segment is mainly attributed to high prevalence of pneumococcal disease in pediatric, elderly, and immunocompromised populations. In addition, growing number of pneumococcal diseases associated with chronic disease patients is further driving the adoption of the pneumococcal vaccines.

The route of administration is the lane by which a vaccine is brought into contact with the body. Vaccines are administered through Intramuscular (IM), Subcutaneous (SC/SQ), oral, and others (intradermal and nasal). In 2017, the intramuscular accounted for the largest share of the of the global vaccines market. The large share of this segment is mainly due to availability of wide range of vaccines for IM.

Subunit, recombinant, polysaccharide, and conjugate vaccines accounted for the largest share of the global vaccines market in 2017. The large share of this segment is mainly attributed to increasing focus of companies towards recombinant and conjugate vaccines, growing prevalence of diseases, and increasing government initiatives.An in-depth analysis of the geographical scenario of the industry provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa) along with the coverage of major countries in each region. North America accounted for largest share of vaccines market in 2017. The large share of this segment is mainly attributed to the well established vaccination program in the region, increasing prevalence of diseases, growing adoption of advanced vaccines, and large pool of key players. The Asia-Pacific vaccines market is expected to grow at a highest CAGR of 8.9%. The growth in the APAC market is mainly attributed to large patient pool, rising prevalence of diseases, growing awareness on vaccination, increasing government initiatives, and expanding presence of key players in this region. In addition, factors such as increasing disposable income and growing awareness about heath in emerging countries are further propelling the demand of vaccines in APAC.


December 12, 2018
Global Vaccines Market Forecasts 2018-2025: Strong Pipeline, Rising Adoption of Vaccination, Increasing Government Focus on Immunization Programs & Technological Progress in Vaccine Administration
The global vaccines market is expected to reach $57.50 billion by 2025 from $33.70 billion in 2018, growing at a CAGR of 7.9%



Further reading


MODULE 1 - How the immune system works - WHO Vaccine Safety Basics


Overview of the Immune System | NIH: National Institute of Allergy and Infectious Diseases


Documentaries, videos and podcasts





Press Trust of India
January 12, 2021
Read more about Vaccine movement begins, 4 airlines to fly 5.6 mn doses from Pune: Puri on Business Standard. Four airlines will operate nine flights to transport 56.5 lakh doses of COVID-19 vaccine from Pune to 13 cities across the country on Tuesday, said Civil Aviation Minister Hardeep Singh Puri.Vaccine movement has started, he said on Twitter, adding
Xand van Tulleken
December 30, 2020
the Guardian
Researchers at the Oxford Vaccine Group's laboratories. Photograph: Andrew Testa/New York Times/Redux/eyevine
Xand van Tulleken
December 30, 2020
the Guardian
We don't know their names, but these scientists have been working tirelessly to fight the pandemic. It's time to say thank you
Kira Ganga Kieffer
December 20, 2020
Los Angeles Times
Vaccine hesitancy has a long history in the United States. Here are three ways to help break through vaccine fears.
Press Trust of India
December 16, 2020
The interim findings of phase 1 clinical trial showed that the vaccine was was well tolerated in all dose groups
December 11, 2020
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today (December 10, 2020) that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted (17 to 4) in support of the FDA granting Emergency Use Authorization (EUA) for the companies' COVID-19 mRNA vaccine (BNT162b2). There is one member of the Committee whose vote is not included in the 17 to 4 vote decision. VRBPAC based its recommendation on the totality of sci...
Lisa Bari
December 11, 2020
Business Insider
J&J's vaccine may provide enough immunity after one dose and is expected to be stable at refrigerator temperatures, which will help scale distribution.
Ramanan Laxminarayan, Susan Fitzpatrick, & Simon Levin
December 9, 2020
Safe, effective, and available vaccines are the best long-term solution to the coronavirus pandemic.1 So it's welcome news that...By Ramanan Laxminarayan, Susan Fitzpatrick, & Simon Levin
Tina Reed
December 8, 2020
Top execs from national retail pharmacy chains CVS and Walgreens say their infrastructure is ready and well-tested for the challenges ahead in distributing the COVID-19 vaccines once they become available.
November 18, 2020
New Scientist
Promising early results from vaccine trials offer hope of defeating covid-19, but vaccines may be less effective in the real world and people's safety concerns could hamper take-up
Michael Le Page, Clare Wilson, Jessica Hamzelou, Sam Wong, Adam Vaughan, Conrad Quilty-Harper and Layal Liverpool
November 20, 2020
New Scientist
The latest coronavirus news updated every day including coronavirus cases, the latest news, features and interviews from New Scientist and essential information about the covid-19 pandemic
Matthew Weber
November 9, 2020
A look at the vaccines in development to fight COVID-19
June 22, 2020
The most immediate effect of vaccine nationalism is that it further disadvantages countries with fewer resources and bargaining power.
June 9, 2020
Voltron Therapeutics, Inc. Enters into Sponsored Research Agreement with The Vaccine & Immunotherapy Center at the Massachusetts General Hospital to Advance the Development of a Personalized Cancer Vaccine - read this article along with other careers information, tips and advice on BioSpace
BS Web Team and PTI
May 30, 2020
The quickest for any vaccine to be prepared is not less than four years, says Kiran Mazumdar-Shaw.
April 17, 2020
Zee Business
With deadly coronavirus showing no sign of slowing down in taking human lives, there is a positive development on the covid 19 pandemic. Get more India News and Business News on Zee Business.
April 16, 2020
BCG Vaccine for Health Care Workers as Defense Against SARS-COV2 - Full Text View.
April 15, 2020
Six Indian companies are working on a vaccine for COVID-19, joining the global race against time to find a preventive for the deadly infection spreading rapidly across the world, says a top Indian scientist.
April 16, 2020
While Zydus Cadila is working on two vaccines, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax are developing one vaccine each, Gagandeep Kang, executive director of the Translational Health Science and Technology Institute, Faridabad, said.
Research and Markets
Invalid Date
DUBLIN, Dec. 12, 2018 /PRNewswire/ -- The "Vaccines Market By Indication (Pneumococcal, Influenza, DTP, HPV, Hepatitis, Meningococcal, Rotavirus, Polio, MMR),...


Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.